PF-07104091 as a Single Agent and in Combination Therapy
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Small Cell Lung Cancer|Ovarian Cancer|Breast Cancer
Interventions: DRUG: PF-07104091 monotherapy dose escalation|DRUG: PF-07104091 + palbociclib + fulvestrant|DRUG: PF-07104091 + palbociclib + letrozole|DRUG: PF-07104091 monotherapy dose expansion (ovarian)|DRUG: PF-07104091 monotherapy dose expansion (SCLC)|DRUG: PF-07104091 + Fulvestrant (post CDK4/6)|DRUG: PF-0704091 + Fulvestrant (post CDK4/6)
Sponsor: Pfizer